|
|
|
| home > epc > autumn 2002 > drug interactions: implications for pharmacogenetics in drug development |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The recent withdrawal of cerivastatin, an effective and clinically popular HMG-CoA reductase inhibitor, highlights the perils of drug-drug interactions that afflict many drugs during their routine clinical use. Cerivastatin was first approved in the USA and the European Union in the middle of 1997 but on 8th August 2001, after a market life of just over four years, Bayer Pharmaceuticals announced that, with immediate effect, they were withdrawing the drug from the markets worldwide. Following post-marketing experience, a major safety-led change was introduced in December 1999 to contraindicate the concurrent administration of cerivastatin and gemfibrozil. However, by August 2001, clinical use of cerivastatin was associated with 31 fatalities due to rhabdomyolysis in the USA. In 12 (39%) of these, cerivastatin was coadministered with gemfibrozil.
Cerivastatin represents the most recent example in a long list of many valuable drugs that have been lost because of their drug interaction potential. Other drugs withdrawn from the market since 1993 due to clinically significant drug interactions observed during their routine clinical use, are shown in Table 1.
Many factors may interact with a drug to alter its disposition or a patient's response to it. These include age, gender, diet, social habits (for example consumption of tobacco or alcohol), physical activity and pathophysiologic states (for example co-morbidity, menstruation). By far the most important factor, however, is the coadministration of another drug resulting in a drug-drug interaction. This brief review is concerned with only the drug-drug interactions.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
2012 BIO International Convention
18-21 June 2012, Boston, Massachusetts
Connect, partner and innovate at the 2012 BIO International Convention, June 18-21, Boston, Mass. Network with 15,000+ global biotech leaders in the BIO Business Forum, Exhibition and Programme.
More info >> |
|
 |
News and Press Releases |
 |
Kallik’s new approach to asset management delivers long term artwork automisation
Marketing and compliance departments can now have greater control over their assets –from logos and images to labelling copy – and a roadmap to automated artwork generation, thanks to Kallik’s online Asset Repository. It is the most cost-effective way to lay the foundation for future automisation of the artwork and labelling generation. The practice of centralising the content in a web-based asset library and reusing those assets across all marketing and trade communications is saving businesses thousands, if not millions, of pounds.
More info >> |
|
|
